1. Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.
- Author
-
Toreli ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, Miranda E, Fechio L, Silva Santos Duarte A, Basso A, Duarte G, Souza Medina S, Pericole F, Benites B, Jones K, Singh H, Farmaha J, Vashisht A, Kolhe R, Mondal AK, Saad STO, de Souza CA, Cortes JE, and Pagnano K
- Subjects
- Humans, Brazil epidemiology, Male, Female, Middle Aged, United States epidemiology, Aged, Adult, Vaccination, Leukemia, Myelogenous, Chronic, BCR-ABL Positive immunology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive epidemiology, COVID-19 immunology, COVID-19 epidemiology, COVID-19 prevention & control, COVID-19 Vaccines immunology, SARS-CoV-2 immunology, Antibodies, Viral blood, Antibodies, Viral immunology
- Abstract
This study investigates COVID-19 outcomes and immune response in chronic myeloid leukemia (CML) patients post-SARS-CoV-2 vaccination, comparing effectiveness of various vaccine options. Data from 118 CML patients (85 in Brazil, 33 in the US) showed similar infection rates prior (14% Brazil, 9.1% US) and post-vaccination (24.7% vs. 27.3%, respectively). In Brazil, AstraZeneca and CoronaVac were the most commonly used vaccine brands, while in the US, Moderna and Pfizer-BioNTech vaccines dominated. Despite lower seroconversion in the Brazilian cohort, all five vaccine brands analyzed prevented severe COVID-19. Patients who received mRNA and recombinant viral vector vaccines (HR: 2.20; 95%CI 1.07-4.51; p < .031) and those that had achieved at least major molecular response (HR: 1.51; 95% CI 1.01-3.31; p < .0001) showed higher seroconversion rates. Our findings suggest that CML patients can generate antibody responses regardless of the vaccine brand, thereby mitigating severe COVID-19. This effect is more pronounced in patients with well-controlled disease.
- Published
- 2024
- Full Text
- View/download PDF